January 20 2026， Simcere Zaiming, an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group (2096.HK) announced today that its bispecific antibody-drug conjugate (BsADC) SIM0610 has dosed first patient in a Phase I clinical trial at the Affiliated Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital）.
This multicenter, open-label Phase I study, led by Academician Jinming Yu of the Affiliated Cancer Hospital of Shandong First Medical University, aims to evaluate the safety and antitumor effects of SIM0610 in patients with locally advanced/metastatic solid tumors.
SIM0610 is a BsADC that simultaneously targets the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (cMET). It consists of a humanized anti-EGFR/cMET bispecific antibody linked via a cleavable hydrophilic linker to a topoisomerase I inhibitor (TOP1i). The mechanism of action involves the bispecific antibody binding to EGFR and/or cMET on the surface of tumor cells, followed by internalization and release of TOP1i, which induces DNA damage and tumor cell apoptosis. By simultaneously inhibiting both targets, SIM0610 aims to enhance antitumor activity, overcome drug resistance, and improve treatment specificity through its favorable plasma stability and hydrophilicity.
SIM0610 has shown significant antitumor efficacy in prelicnical models of NSCLC and colon cancer, suggesting its potential as a novel and effective treatment option for patients with locally advanced or metastatic solid tumors positive for EGFR and/or cMET expression.
About Simcere Zaiming
Simcere Zaiming is an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Limited . Founded in 2023, Simcere Zaiming is dedicated to developing ground breaking therapies to meet the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several innovative products in China, including Enzeshu, COSELA, Enweida, Endosta, and Enlituo. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners.pr@zaiming.com